ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025
Coronene Bisimide as a Visible-Light-Mediated Triplet-Triplet Energy Transfer Catalyst.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Photosensitization has emerged as a versatile tool to facilitate access to excited states under mild conditions, allowing for efficient and selective photochemical transformations. Herein, we report a very simple molecule, coronene bisimide (CBI), as a potent visible-light photosensitizer featuring a high extinction coefficient with a broadband absorption spanning from ultraviolet to green region of the visible spectrum, along with a long-lived triplet state generated via efficient intersystem crossing (ISC). Utilizing the triplet-triplet energy transfer (TTEnT) strategy, CBI catalyzes diverse reactions under green light irradiation. Through this, we propose CBIs as a new class of heavy-atom-free visible-light sensitizers overcoming the limitations of conventional sensitizers, such as low extinction coefficient in the visible regime, short triplet-state lifetimes, and high toxicity, by relying on heavy atoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.